There is renewed interest in the application of psychedelics in psychiatric care. This trial is the first that examines the safety and efficacy of psilocybin-treatment at a larger scale in participants with treatment resistant depression.
We are joined by Renske Blom, resident psychiatry, MD (Sub-I of the psilocybin study) and Metten Somers, psychiatrist, MD , PhD, MBA (PI of the psilocybin study) from the Utrecht Medical Center , Department of Psychiatry affective and psychotic disorder to talk about their study (full event description below).
This lecture will take place in the Medical Faculty of Vrije Universiteit Amsterdam, Room MF-FG2, on 12.04.2019, 6PM. Tickets available online and at the door (if not sold out).
The lecture is free for registered APRA members. It is possible to acquire membership directly on the ticket webshop page or in the link below, granting free/discounted entrance to all APRA events, and more. If you acquire APRA membership through the ticket webpage, please make sure to also fill in the form at this link https://docs.google.com/forms/d/17n-QtIqdQN0uG5D6A7UU5mGgSD7eYmvaMXZKkn60fCI/
Students of the Vrije Universiteit Amsterdam receive a 50% discount as a special offer on our membership fee. A membership grants free access to all of our future events! If you wish to claim your discount, please register first with your VU-mail via: https://goo.gl/forms/D4ZnXucYy9Du0T3k2
For full information on APRA membership see:
Psilocybin occurs naturally in different mushroom-species and is sold in smartshops in the Netherlands as ‘magic truffels’. In the 60’s, psilocybin was synthesized and brought to the market by Sandos as an compound to facilitate enhanced psychotherapy. Since psilocybin appeared on Schedule I of the controlled substances act in 1971, research halted for almost 35 years. In recent years there has been a renewed interest in the use of psilocybin in psychiatric care, for instance as a treatment for depressive symptoms. Two recent studies show a fast and often persistent reduction in depressive symptoms (1,2).
The aim of this study is to assess the safety and efficacy of psilocybin for treatment of treatment resistant depression in a large European multicenter randomized controlled trial. The criterium treatment resistant depression is met, when participants do not respond to at least two antidepressants. This trial recently began inclusions in two centers in The Netherlands: the UMC Utrecht and in the UMC Groningen.
Participants are randomized and will receive a double blind dosage of psilocybin (1mg, 10mg or 25mg). During the psilocybin-session, participants are guided by a trained therapist and a co-therapist. There will also be preparatory and integration sessions with the therapist.
The trial is sponsored by Compass Pathways http://compasspathways.com/ .
1. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry. 2016;3(7):619-627. doi:10.1016/S2215-0366(16)30065-7
2. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181-1197. doi:10.1177/0269881116675513
Locatie Vrije Universiteit Amsterdam MF-FG2
Adres De Boelelaan 1105, 1081 HV Amsterdam
Tijd 18:00 – 20:00